Replies to post #545913 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Correct.

There are approved agents to use for quality of life and symptom management.

The important point is that there is nothing yet approved for rGBM that extends survival.

In other words or in Stupp’s words, survival is always the same with currently approved SOC therapies.

rGBM is a major unmet need.

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847